Syndax Pharmaceuticals (Nasdaq: SNDX) has entered into a $350 million royalty funding agreement with Royalty Pharma (Nasdaq: RPRX).
The deal is focused on US net sales of Niktimvo (axatilimab-csfr), an approved treatment for chronic graft-versus-host disease. The agreement includes a 13.8% royalty on US sales, which will end once Royalty Pharma receives a 2.35 times return on its investment.
The partnership comes amid strong growth for Royalty Pharma, which recently reported a 12% rise in portfolio receipts in the second quarter, beating its high-single-digit forecast. The firm has committed $2 billion in royalty acquisitions and recently increased its 2024 guidance, projecting portfolio receipts to exceed $2.7 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze